COMP <GO>
IQV vs ABBV // FREE CASH FLOW YIELD
IQVIA Holdings Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IQV 5
— ABBV 9
▲ FREE CASH FLOW YIELD LEADER: IQV
LAST: $267.33 (-2.81%) • MKT CAP: $45.33B
fcf-yield
4.24%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IQV VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IQV | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 29.00% | -19.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.4x | 33.3x | -12.90 | IQV | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.24% | 3.47% | +0.77 | IQV | /fcf-yield <GO> |
| Operating Margin | 13.40% | 24.60% | -11.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.30% | 6.90% | +1.40 | IQV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.90% | 8.60% | -2.70 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 5.33 | -3.11 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 72.8 | -23.78 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.15 | +0.01 | IQV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 113.1x | -82.10 | IQV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.33B | $513.86B | -$468.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IQV REV | ABBV REV | IQV GROSS % | ABBV GROSS % | IQV FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.31B | $61.16B | 44.0% | 70.2% | $1.92B | $17.82B |
| FY 2024 | $15.40B | $56.33B | 44.0% | 70.0% | $2.02B | $17.83B |
| FY 2023 | $14.98B | $54.32B | 44.0% | 44.0% | $1.47B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IQV // BETA 1.16
ABBV // BETA 1.15